The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease.
But approval of the drug, called Relyvrio, is bound to stir new questions, with some doubting the strength of data supporting its effectiveness. Patient advocate groups had strongly lobbied the FDA for its approval, however.
